- $31.59m
- $47.91m
- $80.28m
Tela Bio Inc Reports Results For The Quarter Ended In December: Earnings Summary
Brief: Tela Bio Reports Fourth Quarter Results
Tela Bio Inc Expected To Post A Loss Of 55 Cents A Share: Earnings Preview
Brief: Tela Bio Announces U.S. Commercial Launch Of Two New Ovitex® Lpr Device Configurations To Repair Large Abdominal Hernias Using Robotic And Laparoscopic Techniques
Brief: Tela Bio Awarded Biosynthetic Mesh Products Agreement With A National Group Purchasing Organization
Brief: Tela Bio Announces U.S. Commercial Launch Of Its Restoration Solution To Heal Surgical Wounds
REUTERS NEWS SCHEDULE AT 10 a.m. GMT/ 6 a.m. ET
Tela Bio Inc Reports Results For The Quarter Ended In September: Earnings Summary
Brief: Tela Bio Reports Third Quarter 2022 Financial Results
Tela Bio Inc Expected To Post A Loss Of 63 Cents A Share: Earnings Preview
Brief: Tela Bio Announces Publication Of 24-Month Bravo Study Results Demonstrating Benefits Of Ovitex® Reinforced Tissue Matrix In Hernia Repair
TELA Bio drops on pricing stock deal
Brief: Tela Bio Announces Pricing Of Public Offering OF 4.00 Million Common Shares Priced At $8.00per Share
Brief: TELA Bio Announces Proposed Public Offering Of Common Stock
Tela Bio Inc Reports Results For The Quarter Ended In June: Earnings Summary
Brief: Tela Bio Q2 Revenue Rose 38 Percent To $10.4 Million
Tela Bio Inc Expected To Post A Loss Of 62 Cents A Share: Earnings Preview
Brief: TELA Bio Highlights Results from Studies on Benefits of OviTex Reinforced Tissue Matrix in Hernia Repairs
Brief: Tela Bio Awarded Synthetic Bioabsorbable Mesh Products Agreement With Premier, Inc.